Q-omics provides the consensus-scored F13A1 profile across patient tissues and cancer cell-line models. F13A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, F13A1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, F13A1 protein abundance shows 31,303 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KICH, and GBM as cancer lineages where F13A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F13A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F13A1 survival associations across molecular data types. F13A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F13A1 RNA expression–survival associations across cancer types. High F13A1 expression shows unfavorable associations in BLCA, LUSC and KIRP, but favorable associations in LUAD, UCEC and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for F13A1 RNA expression.
This table summarizes F13A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for F13A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F13A1 shows lower tumor expression in KICH, BLCA, COAD, KIRP and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher F13A1 RNA expression in normal versus tumor tissue (log2 FC = −2.590, t-test p < 0.001).
This table shows molecular features associated with F13A1 in patient tissues and cancer cell lines. In patient samples, F13A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, F13A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
